<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00796367</url>
  </required_header>
  <id_info>
    <org_study_id>OB-305</org_study_id>
    <nct_id>NCT00796367</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of VI-0521 to Evaluate the Long Term Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions. An Extension Study of Protocol OB-303 (NCT00553787)</brief_title>
  <official_title>A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Extension Study (From Study OB-303 [NCT00553787]) to Determine the Safety and Efficacy Of VI-0521 for the Long-Term Treatment Of Obesity in Adults With Obesity-Related Co-Morbid Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VIVUS, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medpace, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>VIVUS, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the long-term safety and efficacy of VI-0521
      compared to placebo for the treatment of overweight and obesity in adults who have completed
      study OB-303 (NCT00553787) at selected study sites. This is an extension study of protocol
      OB-303 (NCT00553787).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Weight Change at End of Treatment, Week 108.</measure>
    <time_frame>From baseline to end of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects With at Least 5% Weight Loss at End of Treatment, Week 108.</measure>
    <time_frame>Baseline to End of Treatment</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">676</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VI-0521 Mid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7.5 mg phentermine and 46 mg topiramate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VI-0521 Top</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mg phentermine and 92 mg topiramate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VI-0521</intervention_name>
    <description>7.5 mg phentermine and 46 mg topiramate</description>
    <arm_group_label>VI-0521 Mid</arm_group_label>
    <other_name>Qsymia</other_name>
    <other_name>Qnexa</other_name>
    <other_name>PHEN/TPM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VI-0521</intervention_name>
    <description>15 mg phentermine and 92 mg topiramate</description>
    <arm_group_label>VI-0521 Top</arm_group_label>
    <other_name>Qsymia</other_name>
    <other_name>Qnexa</other_name>
    <other_name>PHEN/TPM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        To be eligible for enrollment into this study, subjects must meet all of the following
        criteria:

          -  Completion of study OB-303 (NCT00553787) on treatment and compliance with all protocol
             requirements

          -  Written informed consent

          -  Female subjects of childbearing potential must be using adequate contraception,
             defined as double-barrier methods, stable hormonal contraception plus single barrier
             method, or tubal ligation. Female subjects are considered to be of childbearing
             potential unless they have undergone a hysterectomy or bilateral oophorectomy, are ≥55
             years of age and experienced spontaneous cessation of menses for at least 1 year, or
             have a documented follicle-stimulating hormone level ≥40 IU/L

          -  Willingness and ability to comply with scheduled visits, treatment plan, laboratory
             tests, and other study procedures.

        Exclusion Criteria:

        Subjects will not be included in the study if they meet any of the following:

          -  Body mass index ≤22 kg/m2 at the completion of study OB-303

          -  Off study medication at completion of study OB-303 (NCT00553787) for longer than 4
             weeks continuously due to an event-driven holiday, or off study medication with no
             plans to restart

          -  Development of any condition during study OB-303 (NCT00553787) that, in the opinion of
             the investigator, would contraindicate the administration of study medication, affect
             compliance, interfere with study evaluations, or confound the interpretation of study
             results

          -  Participation in a formal weight loss program (including: Weight Watchers and related
             dietary/lifestyle intervention programs; prepared food programs; prescribed or over
             the counter weight loss medications; dietary supplement or herbal preparations, teas,
             or tinctures intended for weight loss; or any supervised fast or very low calorie
             diet).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Peterson</last_name>
    <role>Study Director</role>
    <affiliation>VIVUS, Inc.</affiliation>
  </overall_official>
  <link>
    <url>http://www.vivus.com/</url>
    <description>VIVUS company website</description>
  </link>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2008</study_first_submitted>
  <study_first_submitted_qc>November 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2008</study_first_posted>
  <results_first_submitted>July 31, 2012</results_first_submitted>
  <results_first_submitted_qc>July 31, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 31, 2012</results_first_posted>
  <disposition_first_submitted>May 13, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>May 13, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 18, 2011</disposition_first_posted>
  <last_update_submitted>September 5, 2012</last_update_submitted>
  <last_update_submitted_qc>September 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topiramate</mesh_term>
    <mesh_term>Phentermine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were from OB-303 (NCT00553787)</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="P2">
          <title>VI-0521 Mid</title>
          <description>VI-0521 7.5 mg PHEN/46 mg TPM</description>
        </group>
        <group group_id="P3">
          <title>VI-0521 Top</title>
          <description>VI-0521 15 mg PHEN/92 mg TPM</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="227"/>
                <participants group_id="P2" count="154">one participant signed ICF but withdrew from study prior to first dosing in OB-305</participants>
                <participants group_id="P3" count="295"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="197"/>
                <participants group_id="P2" count="129"/>
                <participants group_id="P3" count="248"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="47"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>non compliance</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Requirement for restricted medication</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="B2">
          <title>VI-0521 Mid</title>
          <description>VI-0521 7.5 mg PHEN/46 mg TPM</description>
        </group>
        <group group_id="B3">
          <title>VI-0521 Top</title>
          <description>VI-0521 15 mg PHEN/92 mg TPM</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="227"/>
            <count group_id="B2" value="153"/>
            <count group_id="B3" value="295"/>
            <count group_id="B4" value="675"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.7" spread="9.8"/>
                    <measurement group_id="B2" value="52.2" spread="10.6"/>
                    <measurement group_id="B3" value="51.2" spread="10.4"/>
                    <measurement group_id="B4" value="51.9" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="147"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="195"/>
                    <measurement group_id="B4" value="448"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="100"/>
                    <measurement group_id="B4" value="227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="227"/>
                    <measurement group_id="B2" value="153"/>
                    <measurement group_id="B3" value="295"/>
                    <measurement group_id="B4" value="675"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Weight Change at End of Treatment, Week 108.</title>
        <time_frame>From baseline to end of treatment</time_frame>
        <population>Intent-to-Treat Last observation carried forward (ITT-LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>VI-0521 Mid</title>
            <description>VI-0521 7.5 mg phentermine/46 mg topiramate</description>
          </group>
          <group group_id="O3">
            <title>VI-0521 Top</title>
            <description>VI-0521 15 mg phentermine/92 mg topiramate</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Weight Change at End of Treatment, Week 108.</title>
          <population>Intent-to-Treat Last observation carried forward (ITT-LOCF)</population>
          <units>percent weight loss</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="0.55"/>
                    <measurement group_id="O2" value="-9.32" spread="0.67"/>
                    <measurement group_id="O3" value="-10.5" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>No formal calculation of sample size was conducted due to being an extension study of OB-303 (NCT00553787)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Intersection-union method applied in a step-down testing approach</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>8.71</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.673</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.39</ci_lower_limit>
            <ci_upper_limit>10.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No formal calculation of sample size was conducted due to being an extension study of OB-303 (NCT00553787)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Intersection-union method applied in a step-down testing approach</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.52</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.799</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.95</ci_lower_limit>
            <ci_upper_limit>9.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>No formal calculation of sample size was conducted due to being an extension study of OB-303 (NCT00553787)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1189</p_value>
            <p_value_desc>Intersection-union method applied in a step-down testing approach</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.760</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.31</ci_lower_limit>
            <ci_upper_limit>2.68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With at Least 5% Weight Loss at End of Treatment, Week 108.</title>
        <time_frame>Baseline to End of Treatment</time_frame>
        <population>Intent-to-treat Last-observation-carried-forward (ITT-LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>VI-0521 Mid</title>
            <description>VI-0521 7.5 mg phentermine/46 mg topiramate</description>
          </group>
          <group group_id="O3">
            <title>VI-0521 Top</title>
            <description>VI-0521 15 mg phentermine/92 mg topiramate</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With at Least 5% Weight Loss at End of Treatment, Week 108.</title>
          <population>Intent-to-treat Last-observation-carried-forward (ITT-LOCF)</population>
          <units>percent participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="75.2"/>
                    <measurement group_id="O3" value="79.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>No formal calculation of sample size was conducted due to being an extension study of OB-303 (NCT00553787)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Intersection-union method applied in a step-down testing approach</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>9.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.97</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.24</ci_lower_limit>
            <ci_upper_limit>14.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No formal calculation of sample size was conducted due to being an extension study of OB-303 (NCT00553787)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Intersection-union method applied in a step-down testing approach</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>6.99</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.68</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.36</ci_lower_limit>
            <ci_upper_limit>11.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>No formal calculation of sample size was conducted due to being an extension study of OB-303 (NCT00553787)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2169</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.35</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.32</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>2.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were collected from when written informed consent was provided through 28 days after the last dose of investigational product.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="E2">
          <title>VI-0521 Mid</title>
          <description>VI-0521 7.5 mg PHEN/46 mg TPM</description>
        </group>
        <group group_id="E3">
          <title>VI-0521 Top</title>
          <description>VI-0521 15 mg PHEN/92 mg TPM</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>peptic ulcer hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>inguinal hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>serositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>acute cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>mesothelioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>hemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>transient ischemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>ischemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>nephritic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>renal failure, acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="182" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="111" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="234" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>eye pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>tooth ache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>hemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>edema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>influenza</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>ear infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>viral infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>contusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>weight increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>hemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>abdominal bruit</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>dyslipidemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>paresthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="227"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After Sponsor's written notification that publication of results is no longer planned or 12 months after termination of the study at all sites, Institution &amp; PI may publish, upon written approval from Sponsor, results of the Study. Sponsor will be given the opportunity to review any proposed publication at least 60 days prior to submission for publication or disclosure. Upon Sponsor's written request, Institution and PI shall not publish or disclose information related to the Study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Wesley W Day, PhD</name_or_title>
      <organization>Vivus, Inc</organization>
      <phone>650.934.5200</phone>
      <email>day@vivus.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

